Posted On: 01/21/2016 9:14:39 PM
Post# of 23071
$TROV Pr gap & candle.
Nasdaq CM $5.69
An agreement with America’s Choice Provider Network (ACPN).
Website
Shares Outstanding: 29.72M
Float: 23.62M
% Held by Insiders: 9.48%
% Held by Institutions: 29.40%
Shares Short (as of Dec 31, 2015): 3.61M
Short Ratio (as of Dec 31, 2015): 13.05
Short % of Float (as of Dec 31, 2015): 14.06%
Shares Short (prior month): 3.63M
Headlines
Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It is developing PCM BRAF and KRAS mutation detection tests for detecting mutations in metastatic cancer patients; and HPV HR detection test to detect the presence of various HPV genotypes using a urine sample. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Nasdaq CM $5.69
An agreement with America’s Choice Provider Network (ACPN).
Website
Shares Outstanding: 29.72M
Float: 23.62M
% Held by Insiders: 9.48%
% Held by Institutions: 29.40%
Shares Short (as of Dec 31, 2015): 3.61M
Short Ratio (as of Dec 31, 2015): 13.05
Short % of Float (as of Dec 31, 2015): 14.06%
Shares Short (prior month): 3.63M
Headlines
Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It is developing PCM BRAF and KRAS mutation detection tests for detecting mutations in metastatic cancer patients; and HPV HR detection test to detect the presence of various HPV genotypes using a urine sample. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
(0)
(0)
